Adriana Ioachimescu, MD
Endocrinology, Diabetes & Metabolism · Milwaukee, WINPI 1437183621
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Xeris Pharmaceuticals, Inc. at 43.7% of the total. Among endocrinology, diabetes & metabolism clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $1087.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$11K
- Recordati_rare_diseases_inc.$6K
- Chiasma, Inc.$3K
- HRA Pharma RARE Diseases$2K
- Ipsen Biopharmaceuticals, Inc$2K
- Amryt Pharma Holdings Ltd$1K
- plus $1K from 3 others
Across 121 payments — averaging $3998.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Xeris Pharmaceuticals, Inc.$123K
- Strongbridge US Inc.$111K
- Recordati_rare_diseases_inc.$90K
- Amryt Pharma Holdings Ltd$83K
- Chiasma, Inc.$40K
- Novartis$22K
- plus $15K from 2 others
What the payments were for
- Consulting fees$11,33043%
- Speaking & faculty fees$11,67445%
- Travel & lodging$2,4779%
- Food & beverage$6132%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 13 | $11,401 |
| Recordati_rare_diseases_inc. | 3 | $5,775 |
| Chiasma, Inc. | 2 | $2,950 |
| HRA Pharma RARE Diseases | 1 | $2,000 |
| Ipsen Biopharmaceuticals, Inc | 1 | $1,720 |
| Amryt Pharma Holdings Ltd | 1 | $1,150 |
| Novo Nordisk | 1 | $559 |
| Corcept Therapeutics | 1 | $490 |
| Radius Health, Inc. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RECORLEV$10,770
- MYCAPSSA$4,100
- METOPIRONE$2,000
- SOMATULINE DEPOT$1,720
- ISTURISA$1,375
- Korlym$490
How this compares
$26,095 in reported general payments places this provider in the 90th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cabergoline | 14 | $882 |
| Levothyroxine Sodium | 14 | $144 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Milwaukee
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
- Catherine ZhangMilwaukee$16K
- Timur GusovMilwaukee$5K
- Antoni GofronMilwaukee$5K
- Anil ChandelMilwaukee$3K
- Michael VossMilwaukee$2K
- Olena KlindukhovaMilwaukee$1K
- Usonwanne IbekweMilwaukee$1K
- Veitla RaoMilwaukee$658
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.